The Latest Breaking News from Goldman Sachs

CNBC

Katie Koch, the chief investment officer for public equities at Goldman Sachs Asset Management (GSAM), quips that “Beyoncé is ultimately recession-resistant,” and so are other popular artists.  That’s why the portfolios she helps oversee own shares of live-concert companies in the US and Europe. 

HSBC Holdings Plc has begun an internal review in the face of pressure from its largest shareholder to discuss splitting off the bank's Asian operations.

Goldman Sachs Group's (NYSE:GS) short percent of float has fallen 15.72% since its last report. The company recently reported that it has 4.57 million shares sold short, which is 1.34% of all regular shares that are available for trading.

Goldman Sachs has decided to maintain its Buy rating of Cytek Biosciences (NASDAQ:CTKB) and lower its price target from $14.00 to $12.00. Shares of Cytek Biosciences are trading up 10.93% over the last 24 hours, at $8.22 per share.

 

Hawkish expectations in Asia’s emerging markets are piling up as traders become increasingly convinced that central banks in the region cannot ignore the threat of domestic inflation any longer.

Goldman Sachs has decided to maintain its Buy rating of GoodRx Holdings (NASDAQ:GDRX) and lower its price target from $30.00 to $12.00. Shares of GoodRx Holdings are trading up 1.32% over the last 24 hours, at $8.07 per share.

A whale with a lot of money to spend has taken a noticeably bearish stance on Goldman Sachs Group. Looking at options history for Goldman Sachs Group (NYSE:GS) we detected 21 strange trades.

Reuters US Trucking Downturn Threatens Autonomous Operators like Uber Freight

Goldman Sachs Group Inc (NYSE: GS) investors are suing the bank over the 1MDB scandal and are seeking sworn testimony from three former employees who live in the U.K.